"Sodium-glucose cotransporter-2 inhibitors and abnormal serum potassium: a real-world, pharmacovigilance study"

作者全名："Yu, Meng; Zhao, Subei; Fan, Xiaoyun; Lv, Yuhuan; Xiang, Linyu; Li, Rong"

作者地址："[Yu, Meng; Fan, Xiaoyun] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Med & Pharmaceut Coll, Batch Key Disciplines Publ Hlth Chongqing 1, Chongqing, Peoples R China; [Zhao, Subei; Lv, Yuhuan; Xiang, Linyu; Li, Rong] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, YouYi Rd 1, Chongqing 400016, Peoples R China"

通信作者："Li, R (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, YouYi Rd 1, Chongqing 400016, Peoples R China.; Li, R (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, YouYi Rd 1, Chongqing, Peoples R China."

来源：JOURNAL OF CARDIOVASCULAR MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001260082100008

JCR分区：Q2

影响因子：3

年份：2024

卷号：25

期号：8

开始页：613

结束页：622

文献类型：Article

关键词：hyperkalemia; hypokalemia; pharmacovigilance database; sodium-glucose transporter-2 inhibitors

摘要："BackgroundNew trials indicated a potential of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to reduce hyperkalemia, which might have important clinical implications, but real-world data are limited. Therefore, we examined the effect of SGLT2i on hyper- and hypokalemia occurrence using the FDA adverse event reporting system (FAERS).MethodsThe FAERS database was retrospectively queried from 2004q1 to 2021q3. Disproportionality analyses were performed based on the reporting odds ratio (ROR) and 95% confidence interval (CI).ResultsThere were 84 601 adverse event reports for SGLT2i and 1 321 186 reports for other glucose-lowering medications. The hyperkalemia reporting incidence was significantly lower with SGLT2i than with other glucose-lowering medications (ROR, 0.83; 95% CI, 0.79-0.86). Reductions in hyperkalemia reports did not change across a series of sensitivity analyses. Compared with that with renin-angiotensin-aldosterone system inhibitors (RAASi) alone (ROR, 4.40; 95% CI, 4.31-4.49), the hyperkalemia reporting incidence was disproportionally lower among individuals using RAASi with SGLT2i (ROR, 3.25; 95% CI, 3.06-3.45). Compared with that with mineralocorticoid receptor antagonists (MRAs) alone, the hyperkalemia reporting incidence was also slightly lower among individuals using MRAs with SGLT-2i. The reporting incidence of hypokalemia was lower with SGLT2i than with other antihyperglycemic agents (ROR, 0.79; 95% CI, 0.75-0.83).ConclusionIn a real-world setting, hyperkalemia and hypokalemia were robustly and consistently reported less frequently with SGLT2i than with other diabetes medications. There were disproportionally fewer hyperkalemia reports among those using SGLT-2is with RAASi or MRAs than among those using RAASi or MRAs alone."

基金机构：First Batch of Key Disciplines on Public Health in Chongqing

基金资助正文：This work was supported by The First Batch of Key Disciplines on Public Health in Chongqing.